Table of contents:
Video: Genetic Diseases And Artificial Intelligence: An Innovative Approach
After invading healthcare, artificial intelligence has since contributed to more effective screening for breast cancer, brain tumor and so on. And thanks to a strategic partnership that has recently emerged, this revolutionary technology will significantly contribute to studies aimed at accelerating and facilitating the diagnosis and treatment of genetic diseases. Explanation.
Artificial intelligence will promote the diagnosis and treatment of genetic diseases
Currently, 3 million French people and 50 million people in the Mediterranean region are affected by rare genetic diseases. Over 95% of patients, including a considerable number of children, do not have adequate treatment. What's more, in the majority of cases, the conditions are very serious, chronic, and affect the whole family. That is why an innovative approach is so necessary.
And in this context, the Institute of Genetics for Patients, Therapies, Innovation and Science (GIPTIS) and the company Genomic Vision announced their partnership aimed at improving the treatments and care given to people with genetic diseases. specific. In particular, this association includes a large number of long-awaited research programs and new tests. But what do these two companies represent and what exactly are they involved in?
GIPTIS was founded by Professor Nicolas Lévy, head of the Department of Medical Genetics at the Timone Hospital. It confirms its ambitions to treat patients quickly and in a much more efficient manner. To this must be added the acceleration of diagnosis, the development of research and treatment. Lévy further asserts that Genomic Vision's powerful new generation technology helps decode complex genetic diseases, ensuring the partnership's success.
Genomic Vision specializes in biotechnology and more particularly in the development of molecular tools based on artificial intelligence. They are currently monitoring DNA replication in cancer cells in order to be able to better detect cancer and genetic diseases.
According to Genomic Vision Founder and CEO Aaron Bensimon, these two companies are “the right partners” and can undoubtedly develop a revolutionary approach.